CT scans track hip implant movement to predict Long-Term stability

NCT ID NCT07698717

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study tracks 30 people receiving a CATALYSTEM cementless hip implant to measure how much the stem moves (subsides) in the thigh bone over two years. Using specialized CT scans, researchers aim to see if the implant stays firmly in place, which is key for long-term success. Participants must have hip osteoarthritis and need a first-time total hip replacement.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CATALYSTEM Cementless Primary Hip System
What this could lead to
If the implant shows stable positioning, it may support its use for long-lasting hip replacement outcomes.
What could go wrong
This is a small, early-stage imaging study, not a test of clinical benefits or risks. Results may not predict real-world performance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient requires primary unilateral THA for a severely painful and/or disabled joint from osteoarthritis, traumatic arthritis, rheumatoid arthritis, avascular necrosis, or congenital dysplasia. 2. Patients is at least 21 years old at the time of informed consent. 3. Patient is able to read and comprehend the informed patient consent document and willing and able to provide informed patient consent for participation in the study and have authorized the transfer of his/her information for study purposes. 4. Patient is able and willing to return for follow-up as specified by the study protocol. 5. Patient is able and willing to complete the required questionnaires and patient-completed portions of the study protocol. Exclusion Criteria: 1. Patient requires implants other than the planned components or would not be a candidate for allowable components to be used (see 4) in the judgement of the surgeon. 2. Patient is planned to have simultaneous bilateral hip arthroplasty 3. Patient had contralateral hip arthroplasty less than 6 months prior to the day of surgery. 4. Patient is expected to have contralateral hip arthroplasty in the following 6 months at the time of consent into this study. 5. Patient has active local or systemic infection. 6. Patient has amputations in either leg that would impact rehabilitation following surgery. 7. Patient has loss of musculature, neuromuscular compromise or vascular compromise that would impact rehabilitation following surgery. 8. Patient has poor bone quality, such as osteoporosis, where in the surgeon's opinion, there could be considerable migration of the prosthesis, or require additional fixation, or a significant chance of periprosthetic fracture, or the lack of adequate bone to support the implant(s). 9. Patient has Charcot's or Paget's disease. 10. Patient is pregnant or lactating. 11. Patient is bedridden. 12. Patient has participated in a clinical investigation with an investigational product (drug or device) in the last 3 months. 13. Patient is currently involved in any personal injury litigation, medical-legal or worker's compensation claims. 14. Patients is, in the opinion of the surgeon, a drug or alcohol abuser or has psychological disorder(s) that could affect their ability to complete patient-reported questionnaires or be compliant with follow-up requirements. 15. Patient is diagnosed and taking prescription medications to treat a muscular disorder that limits mobility due to severe stiffness and pain such as fibromyalgia or polymyalgia.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Avascular necrosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Orthopaedic Innovation Centre

    Winnipeg, Manitoba, R2K 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.